ZYBERNO
Stock Report
Updated Aug 31, 2026

ULTRAGENYX PHARMACEUTICAL INC. (RARE)

Healthcare • NASDAQ

$25.61
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company headquartered in Novato, California, that develops and commercializes novel products for the treatment of rare and ultra-rare genetic diseases. The company's approved products include Dojolvi (triheptanoin) for fatty acid oxidation disorders, Crysvita (burosumab) for X-linked hypophosphatemia, Evkeeza (evinacumab) for familial hypercholesterolemia, and Mepsevii for Sly syndrome.

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
24.0/100
POOR BUSINESS
ULTRAGENYX PHARMACEUTICAL INC. (RARE) scores 24/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-73.6%)
Return on Capital (Capital Efficiency):CRITICAL (-34.8%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

ULTRAGENYX PHARMACEUTICAL INC. (RARE) stock report — Zyberno Score 24/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, RARE generated -$502.20M in Owner Earnings. Capital was deployed as follows: $5.68M invested in capital expenditures. Reinvestment rate: 7.3%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:25.61
Market Cap:$2.61B

Valuation Multiples (2)

P/S Ratio:3.64x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$2.54B

Price Action & Momentum (3)

Momentum Percentile:30 / 100
% of 52-Week High:64.2%
B. Profitability Assessment

Return Metrics (4)

ROA:-44.4%
Reinvestment Rate:7.3%
Fundamental Growth Rate (g):-2.6%

Margin Analysis (3)

Operating Margin Ttm:-73.6%
Net Margin Ttm:-81.7%
Ebitda Margin:-68.9%

TTM Performance (2)

Operating Margin Ttm:-73.6%
Net Margin Ttm:-81.7%

Yield Metrics (2)

Earnings Yield:-$22.76
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:27.5%
Latest Earnings Filed:2026-08-05

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):21.6%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.73x
Quick Ratio:1.56x
Cash Ratio:0.36x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:255,000,000.00
Cash And Cash Equivalents:125,000,000.00
Long Term Debt:$41.00M
Net Debt:-$69.00M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $717.21M
Linear Growth: 21.6%
📊 Click to view full RARE Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$528.17M

Bottom Line Performance (3)

-$585.97M
Income Before Tax:-$582.23M
Ebitda Ttm:-494,163,000.00

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:773,492,000.00
Sga Expense:350,557,000.00
Income Tax Expense:$3.74M
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:361.4%
Sga To Revenue Percentage:163.8%
Ebitda Margin:-68.9%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$1.26B
Current Assets:$606.00M
Ppe Net:235,000,000.00
Goodwill:44,000,000.00
Intangible Assets:$172.00M

Liability Structure (4)

Total Liabilities:1,548,000,000.00
Current Liabilities:351,000,000.00
Long Term Debt:$41.00M
Short Term Debt:$15.00M

Equity & Capital (3)

Equity:-$291.00M
Retained Earnings:-$4.81B
Common Stock:250,000,000.00

Working Capital Items (3)

Accounts Receivable:200,000,000.00
Inventory:59,000,000.00
Accounts Payable:221,000,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:34,000,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$496.53M-$502.20M

Investment Activities (2)

Investing Cash Flow:-$49.00M
Capital Expenditures Ttm:5,676,000.00

Financing Activities (3)

Financing Cash Flow:$394.19M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:34,010,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-5.83
-$5.83
Earnings Per Share Ttm:-$5.75

Revenue & Cash Per Share (2)

Sales Per Share Ttm:7.04
Operating Cash Flow Per Share:-$4.57

Book Value & Capital (2)

Book Value Per Share:-$2.86
Cash Per Share:1.23

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.54x
Working Capital Turnover Ttm:2.81x

Receivables Management (2)

Receivables Turnover Ttm:3.59x
Days Sales Outstanding Ttm:101.78

Inventory Management (2)

Inventory Turnover Ttm:12.16x
Days Inventory Outstanding Ttm:30.03

Payables & Cash Cycle (2)

Days Payable Outstanding:112.47
Cash Conversion Cycle:19.34
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$502.20M

Damodaran Growth Analysis (2)

Reinvestment Rate:7.3%
Fundamental Growth Rate (g):-2.6%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):21.6%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-45.2%
C. Company Profile & Context

Corporate Information (6)

Symbol:RARE
Company Name:ULTRAGENYX PHARMACEUTICAL INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:101.90M
Shares Outstanding Basic:101.90M
Shares Outstanding Diluted:101.90M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 04:38:31 UTC
Data Timestamp:2026-08-31T04:38:31.142911
Scroll to Top